All In MedTech

Device Trial Radar · NCT07069738

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 850 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

850

Planned (sponsor's estimate)

Start

Oct 22, 2025

Primary completion

Nov 2029

Study completion Nov 2029

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Jul 17, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT). 2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.

Conditions

  • Heart Failure - NYHA II - IV

Interventions

  • CRT-D with a Quadripolar LV leadDevice

    Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead.

  • CRT-D with INGEVITY+ pace/sense leadDevice

    Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.Time frame: Through study completion, up to maximum of 5 years
  2. System-related complication-free rateTime frame: 12 months

Locations

43 sites in 1 country. Site status is shown where the registry gives one.

  • Heart Center Research, LLC

    Huntsville, Alabama · Recruiting

  • Mobile Infirmary Medical Center

    Mobile, Alabama · Recruiting

  • Mayo Clinic Phoenix

    Phoenix, Arizona · Recruiting

40 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.